deltatrials
Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00525642

Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer

A Chinese Multi-Center,Randomized Study of Combination or Sequential Use of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy for Node Positive Breast Cancer

Sponsor: Fudan University

Conditions Adjuvant Breast Neoplasms Chemotherapy
Interventions Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
Updated 4 times since 2017 Last updated: Sep 4, 2007 Started: Jun 30, 2003 Completion: Jun 30, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Adjuvant and Breast Neoplasms and is currently ongoing. Fudan University leads this study, which shows 4 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jan 2021 · 48 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 24 months · monthly snapshotUnknown

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2/PHASE3

    Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2_PHASE3

  4. Jan 2017 — Jan 2021 [monthly]

    Unknown Status PHASE2_PHASE3

    First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fudan University
Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations